Welcome to our dedicated page for Vigil Neuroscience SEC filings (Ticker: VIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vigil Neuroscience, Inc. (VIGL) SEC filings archive provides access to the company’s historical regulatory documents from its time as an independent public issuer through its acquisition by Sanofi. As a clinical-stage biotechnology company focused on microglia and TREM2-targeted therapies for neurodegenerative diseases, Vigil used its SEC reports to describe its pipeline, risk factors, and corporate developments.
Key filings include Form 8-K current reports detailing material events. One Form 8-K describes the completion of the merger on August 5, 2025, in which a wholly owned Sanofi subsidiary merged with and into Vigil, with Vigil surviving as a wholly owned subsidiary of Sanofi. That filing explains the merger consideration for common shareholders, treatment of equity awards, the resulting change in control, and the steps taken to delist and deregister Vigil’s common stock.
For trading status and listing history, investors can review the Form 25 (25-NSE) filed by The Nasdaq Stock Market LLC, which formally removed Vigil’s common stock from listing and registration under Section 12(b) of the Exchange Act. Subsequently, Vigil filed a Form 15 (15-12G) to terminate registration of its common stock under Section 12(g) and suspend its reporting obligations under Sections 13 and 15(d), noting an approximate single holder of record at the time of certification.
Earlier periodic reports and registration statements (not reproduced here) historically contained detailed disclosures on Vigil’s TREM2 agonist programs, including iluzanebart for ALSP and VG-3927 for Alzheimer’s disease, as well as financial statements and risk discussions typical for a clinical-stage biotechnology company. On this page, AI-powered tools can help summarize complex filings, highlight key sections related to the Sanofi transaction, and clarify the implications of delisting, deregistration, and contingent value rights for former VIGL shareholders.
Vigil Neuroscience, Inc. (VIGL) – Form 4 filing (08/05/2025)
Chief Medical Officer Dr. Petra Kaufmann reported the disposition of all outstanding stock options in connection with the closing of the merger between Vigil and Sanofi. At the 08/05/2025 effective time, Sanofi’s wholly-owned subsidiary merged with Vigil, making Vigil a wholly-owned Sanofi unit.
- Cash consideration to shareholders: every Vigil common share was converted into $8.00 in cash plus one contingent value right (CVR) worth up to $2.00 upon a specified clinical milestone.
- Options cancelled & cashed-out: 144,000 options (exercise $2.19) and 330,000 options (exercise $3.14) were cancelled. Holders receive cash equal to the spread versus $8.00 plus one CVR per underlying share.
- Acceleration: all unvested options became fully vested before cancellation.
- Following the transaction, Dr. Kaufmann reports zero derivative securities remaining.
The filing confirms consummation of the Sanofi acquisition and crystallises value for option holders and common shareholders.
Vigil Neuroscience, Inc. (VIGL) – Form 4, filed 08/05/2025
Director Bruce Booth reports the disposition of all directly and indirectly held equity in connection with the closing of VIGL’s merger with Sanofi. On the effective date, each share of VIGL common stock was converted into the right to receive $8.00 in cash plus one contingent value right (CVR) worth up to $2.00 upon achievement of a clinical milestone.
- Common shares disposed: 5,000 RSUs (direct), 4,808,896 shares (Atlas Venture Fund XII, L.P.), 1,027,978 shares (Atlas Venture Opportunity Fund I, L.P.).
- Stock options disposed: 144,446 options with exercise prices between $2.19 – $3.39 were accelerated, cashed out for the cash-merger spread, and exchanged for CVRs.
- All unvested RSUs and options became fully vested immediately prior to closing.
- Post-transaction, the reporting person holds no beneficial ownership of VIGL securities.
The filing confirms that VIGL is now a wholly owned Sanofi subsidiary and that legacy shareholders and option/RSU holders have received the stated merger consideration.
Vigil Neuroscience (VIGL) – Form 4 insider filing
President & CEO Ivana Magovcevic-Liebisch reports the disposition of all directly held equity in connection with the 08/05/2025 closing of Vigil’s merger with Sanofi. At the effective time each outstanding share of common stock converted into the right to receive $8.00 cash plus one contingent value right (CVR) worth up to $2.00, subject to a clinical milestone.
The filing shows 222,687 common shares and eight option grants covering roughly 2.96 million shares marked “D” (disposed). Unvested options were accelerated, then: (i) options with strike < $8 were cashed out for the in-the-money spread and granted one CVR per underlying share; (ii) options with strike ≥ $8 and < $10 were exchanged solely for CVRs, with potential incremental cash if the milestone is achieved. Following these transactions the reporting person lists 0 derivative holdings and retains rights only to the merger consideration.
Vigil Neuroscience, Inc. (VIGL) – Form 4 (Insider Transaction)
Director Gerhard Koenig reported the disposition of all remaining equity interests on 08/05/2025, coinciding with the closing of Vigil’s merger with Sanofi. At the effective time, each outstanding share of Vigil common stock was automatically converted into the right to receive $8.00 in cash plus one contingent value right (CVR) worth up to an additional $2.00, together defined as the “Merger Consideration.”
Koenig’s holdings affected:
- 5,000 restricted stock units (reported as common stock) – cancelled for cash + CVR.
- 110,175 stock options across seven grants (exercise prices $1.89-$6.02) – all vested, cancelled, and cashed out for the intrinsic value difference versus the $8.00 cash price, plus one CVR per underlying share.
Post-transaction, Koenig reports 0 shares and 0 derivative securities, reflecting full exit following Vigil’s transition to a wholly owned Sanofi subsidiary.